MarketCap
Facebook
X
Telegram
Exicure Net Income | XCUR
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Exicure
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.95 M | -9.7 M | -16.9 M | -2.58 M | -64.1 M | -24.7 M | -26.3 M | -22.4 M | -12 M | -16.9 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.58 M | -64.1 M | -20.1 M |
Quarterly Net Income Exicure
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.83 M | -2.44 M | -2.62 M | 3.01 M | - | -1.09 M | -600 K | -829 K | - | -5.26 M | -5.76 M | -4.41 M | - | -5.16 M | -7.47 M | -8.35 M | - | -23.5 M | -14.3 M | -12.5 M | -12.7 M | -8.82 M | -4.31 M | 1.15 M | -9.98 M | -5.82 M | -5.22 M | -5.29 M | -4.76 M | -5.32 M | -6.82 M | -5.51 M | -3.44 M | -1.93 M | -2.98 M | -2.65 M | - | -3.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.01 M | -23.5 M | -5.48 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
PDS Biotechnology Corporation
PDSB
|
-7.56 M | $ 1.22 | 4.27 % | $ 56.6 M |  USA |
 |
Pfizer
PFE
|
7.77 B | $ 29.39 | -0.22 % | $ 167 B | USA |
 |
Pharming Group N.V.
PHAR
|
33 M | $ 12.32 | 0.16 % | $ 8.49 B |  Niderland |
 |
Orgenesis
ORGS
|
-48.2 M | - | -33.86 % | $ 61.2 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-785 M | $ 53.74 | -3.26 % | $ 6.45 M | USA |
 |
Фармсинтез
LIFE
|
-525 M | - | - | - |  Russia |
 |
Prothena Corporation plc
PRTA
|
-244 M | $ 7.93 | 0.51 % | $ 427 M | USA |
 |
Codiak BioSciences
CDAK
|
-37.2 M | - | -55.98 % | $ 2.15 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-147 M | $ 10.54 | 7.55 % | $ 1.47 B |  France |
 |
Rocket Pharmaceuticals
RCKT
|
-223 M | $ 2.38 | -2.05 % | $ 264 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
4.5 B | $ 904.69 | 0.2 % | $ 94.6 B | USA |
 |
Replimune Group
REPL
|
-314 M | $ 21.67 | 8.24 % | $ 2.01 B | USA |
 |
DiaMedica Therapeutics
DMAC
|
-32.8 M | $ 9.47 | 4.76 % | $ 445 M | USA |
 |
Royalty Pharma plc
RPRX
|
771 M | $ 67.31 | -0.39 % | $ 28.9 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
-197 K | $ 111.51 | 6.18 % | $ 7.25 B | USA |
 |
Puma Biotechnology
PBYI
|
31.1 M | $ 8.28 | -15.25 % | $ 414 M | USA |
 |
SIGA Technologies
SIGA
|
23.3 M | $ 3.12 | 4.55 % | $ 223 M | USA |
 |
Sage Therapeutics
SAGE
|
-401 M | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
25.4 M | - | - | $ 1.62 B |  Israel |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-6.13 M | $ 61.62 | -2.21 % | $ 172 M | Israel |
 |
SELLAS Life Sciences Group
SLS
|
-26.9 M | $ 8.41 | 6.73 % | $ 917 M | USA |
 |
Summit Therapeutics
SMMT
|
-1.08 B | $ 16.34 | 15.15 % | $ 12.2 B |  Britain |
 |
Cabaletta Bio
CABA
|
-168 M | $ 1.3 | 1.17 % | $ 131 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-285 M | $ 9.53 | 1.39 % | $ 826 M | USA |
 |
Sanofi
SNY
|
7.85 B | $ 47.06 | 0.32 % | $ 57.4 B | France |
 |
Forma Therapeutics Holdings
FMTX
|
-173 M | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
-67.1 M | - | - | $ 8.14 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
521 M | - | - | $ 26.6 B |  Irlanda |
 |
Sarepta Therapeutics
SRPT
|
-713 M | $ 17.8 | 0.68 % | $ 1.78 B | USA |
 |
Paratek Pharmaceuticals
PRTK
|
-63.6 M | - | - | $ 121 M | USA |
 |
China SXT Pharmaceuticals
SXTC
|
-6.21 M | $ 2.84 | -3.07 % | $ 1.93 M |  China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
108 B | $ 21.02 | -0.92 % | $ 33.2 B |  Japan |
 |
Tarsus Pharmaceuticals
TARS
|
-66 M | $ 68.11 | 0.87 % | $ 2.85 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-44.2 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Bio-Techne Corporation
TECH
|
182 M | $ 72.78 | 0.17 % | $ 11.4 B | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
1.41 B | $ 42.32 | 1.33 % | $ 48.5 B | Israel |
 |
RedHill Biopharma Ltd.
RDHL
|
-8.27 M | $ 0.43 | 0.45 % | $ 5.3 B | Israel |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Unity Biotechnology
UBX
|
-26 M | - | -33.41 % | $ 3.37 M | USA |
 |
iTeos Therapeutics
ITOS
|
-134 M | - | - | $ 411 M | USA |
 |
Shattuck Labs
STTK
|
-48.8 M | $ 4.59 | 2.78 % | $ 319 M | USA |
 |
Seelos Therapeutics
SEEL
|
-37.9 M | - | -47.76 % | $ 6.27 M | USA |
 |
Evogene Ltd.
EVGN
|
-7.83 M | $ 0.28 | -16.14 % | $ 2.2 M | Israel |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Protara Therapeutics
TARA
|
-57.4 M | $ 2.33 | 9.15 % | $ 99.8 M | USA |
 |
Trevi Therapeutics
TRVI
|
-42.8 M | $ 14.33 | 11.87 % | $ 1.93 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-10.3 M | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Fennec Pharmaceuticals
FENC
|
-9.74 B | $ 9.79 | 4.26 % | $ 280 M | USA |
 |
Kiromic BioPharma
KRBP
|
-26.9 M | - | 6.61 % | $ 3.08 M | USA |